abstract |
The present invention relates to tryptophan hydroxylase (TPH), useful for the treatment of peripheral serotonin related diseases or disorders, including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone density diseases, and serotonin syndrome, and cancer; It relates in particular to spirocyclic compounds which are inhibitors of isoform 1 (TPH1). |